Skip to main content
Premium Trial:

Request an Annual Quote

LumiGene Inks Reverse Acquisition Pact with Pole Perfect; Dances into Public Market

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – LumiGene today announced it has signed a letter of intent to be acquired by dance studio Pole Perfect Studios in a reverse acquisition that will take LumiGene public.

Upon completion of the deal, LumiGene will become the primary focus of the combined company.

Terms of the deal were not disclosed.

LumiGene, based in Mississauga, Ontario, develops point-of-care diagnostics. Its main technology is the PosiChek Diagnostic System, an automated nucleic acid testing system for preparing and amplifying nucleic acid for the detection of disease-causing pathogens within one hour.

Pole Perfect, based in Longwood, Fla., operates a dance studio "that offers a full line of services not traditionally found at health and fitness centers that will cater to both genders," according to a document filed with the US Securities and Exchange Commission. The company's stock is traded on the over-the-counter bulletin board under the ticker symbol PPFT. Its last trade was on July 29 at $.14.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.